# Phase II Clinical Clical of the Pure Protein Derivatives of BCG

> **NCT06975774** · PHASE1 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Purified Protein Derivative of BCG（BCG-PPD）

## Key facts

- **NCT ID:** NCT06975774
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-26
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-01-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975774, "Phase II Clinical Clical of the Pure Protein Derivatives of BCG". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06975774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*